PubRank

Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis.

PubWeight™: 1.05‹?› | Rank: Top 15%

🔗 View Article (PMID 24879926)

Published in Clin Gastroenterol Hepatol on May 28, 2014

Authors

David S Kotlyar1, James D Lewis2, Laurent Beaugerie3, Ann Tierney4, Colleen M Brensinger4, Javier P Gisbert5, Edward V Loftus6, Laurent Peyrin-Biroulet7, Wojciech C Blonski8, Manuel Van Domselaar9, Maria Chaparro5, Sandipani Sandilya10, Meenakshi Bewtra2, Florian Beigel11, Livia Biancone12, Gary R Lichtenstein13

Author Affiliations

1: Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland; Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
2: Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
3: Gastroenterology, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Saint- Antoine, Université Pierre et Marie Curie Paris-VI, Paris, France.
4: Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
5: Gastroenterology, La Princesa University Hospital, Instituto de Investigación Sanitaria Princesa (IP) and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.
6: Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.
7: Inserm U954, Department of Gastroenterology, Nancy University Hospital, Nancy, France.
8: Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Department of Medicine, SUNY Upstate, Binghamton Campus, Binghamton, New York; Medical University, Wroclaw, Poland.
9: Gastroenterology, Hospital Ramón y Cajal, Madrid, Spain.
10: Division of Nephrology, Department of Medicine, Montefiore Medical Center, Bronx, New York.
11: Department of Medicine, University of Munich-Grosshadern, Munich, Germany.
12: GI Unit, Department of Medicine, University of Tor Vergata, Rome, Italy.
13: Division of Gastroenterology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. Electronic address: grl@mail.med.upenn.edu.

Articles citing this ↘

Association Between Breast Cancer Recurrence and Immunosuppression in Rheumatoid Arthritis and Inflammatory Bowel Disease: A Cohort Study. Arthritis Rheumatol (2016) 1.38

Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res (2015) 0.94

Real-life outcome of anti-tumor necrosis factor α in the ambulatory treatment of ulcerative colitis. World J Gastroenterol (2015) 0.86

Second Korean guidelines for the management of Crohn's disease. Intest Res (2017) 0.82

Epstein Barr virus-positive mucocutaneous ulcer of the colon associated Hodgkin lymphoma in Crohn's disease. World J Gastroenterol (2015) 0.82

Large B-Cell Lymphoma in an Adolescent Patient With Interleukin-10 Receptor Deficiency and History of Infantile Inflammatory Bowel Disease. J Pediatr Gastroenterol Nutr (2016) 0.81

Pharmacologic therapy for inflammatory bowel disease refractory to steroids. Clin Exp Gastroenterol (2015) 0.77

Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology (2016) 0.77

Care of inflammatory bowel disease patients in remission. Gastroenterol Rep (Oxf) (2016) 0.75

How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease? World J Gastroenterol (2015) 0.75

Recurrent Hepatocellular Carcinoma in Patient with Crohn's Disease: Incidental or Expected Outcome of Azathioprine? Case Rep Gastrointest Med (2015) 0.75

Impact on Life Expectancy of Withdrawing Thiopurines in Patients with Crohn's Disease in Sustained Clinical Remission: A Lifetime Risk-Benefit Analysis. PLoS One (2016) 0.75

Healthcare maintenance in elderly patients with inflammatory bowel disease. Ann Gastroenterol (2017) 0.75

The Changing Phenotype of Inflammatory Bowel Disease. Gastroenterol Res Pract (2016) 0.75

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on  Maintenance Treatment. Int J Mol Sci (2017) 0.75

Management of Crohn's disease in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease. Intest Res (2017) 0.75

Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014. BMJ (2017) 0.75

Risk Factors for Rescue Therapy in Crohn's Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up. Dig Dis Sci (2017) 0.75

Articles by these authors ⇆

Effectiveness and Safety of Immunomodulators With Anti-Tumor Necrosis Factor Therapy in Crohn's Disease. Clin Gastroenterol Hepatol (2015) 0.91